Peptides DB

Research-centric peptide and protocol reference hub

GHK-Cu vs Semax

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

GHK-Cu: Research use — not FDA-approvedSemax: Research use — not FDA-approved

A data-driven comparison of GHK-Cu and Semax (also searched as Semax vs GHK-Cu) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

GHK-Cu centers on skin, while Semax leans toward neuro. On indexed research, GHK-Cu is ahead (GHK-Cu: 5 studies, Preclinical; Semax: 4, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • GHK-Cu is strongest for skin; Semax for neuro.
  • Evidence: GHK-Cu Preclinical (5 studies) vs Semax Preclinical (4).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
GHK-CuSemax

At a glance

GHK-CuPreclinical

Copper Peptide | Skin Regeneration & Anti-Aging Compound

Strongest: SkinStudies: 5Level: Well Studied
SemaxPreclinical

Synthetic ACTH Analog | Nootropic & Neuroprotective Peptide

Strongest: NeuroStudies: 4Level: Well Studied

GHK-Cu vs Semax: side-by-side

MetricGHK-CuSemax
ClassSkinCognitive
Regulatory statusResearch use onlyResearch use only
Evidence gradePreclinicalPreclinical
Studies indexed54
Research levelWell StudiedWell Studied
Strongest effectSkin & aestheticsNeuro & mood
Healing & recovery4.01.0
Muscle & body comp1.00.0
Metabolic & appetite3.00.0
Neuro & mood2.04.0
Sleep & circadian0.00.0
Inflammation & immune4.02.0
Skin & aesthetics5.00.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyGHK-CuSemax
MechanismCopper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signalingACTH(4–10) analog; neuroprotective / nootropic
RouteTopical / subcutaneousIntranasal (research use)

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is GHK-Cu?

Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.

Full GHK-Cu profile, mechanism & studies →

What is Semax?

### Summary Semax is a synthetic peptide derived from the adrenocorticotropic hormone (ACTH) that has been investigated for its potential neuroprotective and cognitive-enhancing effects. Research suggests that Semax may influence various biological pathways, including neuroinflammation and intracellular calcium dynamics.

Full Semax profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingGHK-Cu4.0/5 effect signal
MuscleGHK-Cu1.0/5 effect signal
MetabolicGHK-Cu3.0/5 effect signal
NeuroSemax4.0/5 effect signal
InflammationGHK-Cu4.0/5 effect signal
SkinGHK-Cu5.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack GHK-Cu and Semax?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

GHK-Cu vs Semax: side effects

GHK-Cu
  • improved skin texture18
  • localized irritation5
  • transient tingling4
  • gi upset1
  • headache1
Semax

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

GHK-Cu has 5 approved studies indexed (Preclinical), and Semax has 4 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is GHK-Cu or Semax better?

It depends on your goal. GHK-Cu is strongest for skin; Semax for neuro. GHK-Cu has more indexed studies (5). See the goal-by-goal breakdown above.

Is GHK-Cu or Semax better for weight loss?

GHK-Cu shows the stronger metabolic & appetite profile (3.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is GHK-Cu or Semax better for muscle?

GHK-Cu leads on the muscle & body-composition axis (1.0/5).

Which has more research, GHK-Cu or Semax?

GHK-Cu has 5 approved studies indexed (Preclinical); Semax has 4 (Preclinical). Higher counts mean more to read, not proven superiority.

Can you stack GHK-Cu and Semax?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of GHK-Cu vs Semax?

GHK-Cu: community-reported improved skin texture, localized irritation, transient tingling. Semax: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is GHK-Cu or Semax FDA-approved?

GHK-Cu is a research-use compound and is not FDA-approved. Semax is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Semax better than GHK-Cu?

For neuro, Semax has the edge; for skin, GHK-Cu does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

GHK-Cu and Semax are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.